Neurocrine Q3 INGREZZA sales $486M (+29% YoY); raises 2023 guidance to $1.82-1.84B

NEUROCRINE BIOSCIENCES INC

2023-Q3 EPS reported $1.01 revenue$1,371,900,000

INGREZZA Q3 net sales $486M (+29% YoY); total product sales $492M.
GAAP EPS $0.82; non-GAAP EPS $1.54. Cash & securities $1.55B.
INGREZZA 2023 net sales guidance raised to $1.82-1.84B.
FDA approved INGREZZA for Huntington's chorea; NDA accepted for oral granules (PDUFA Apr 30, 2024).
Phase 3 crinecerfont met primary endpoints in adult and pediatric CAH; Analyst Day Dec 5.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

NEUROCRINE BIOSCIENCES INC updated its the third quarter ended September 30, 2023 guidance (raised).

Period: the third quarter ended September 30, 2023
Guidance: raised
Result: reported results

Exact text from the filing

On October 31, 2023, Neurocrine Biosciences, Inc. announced its financial results for the third quarter ended September 30, 2023.

View on SEC.gov

38 earnings releases filed in the last 30 days. Browse all earnings releases →

NEUROCRINE BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0000914475-23-000072

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.